



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Could nucleocapsid be a next-generation COVID-19 vaccine candidate - author's reply

Bryan Orons , Christopher Larson , Scott Caroen , Tony R. Reid

PII: S1201-9712(22)00587-2  
DOI: <https://doi.org/10.1016/j.ijid.2022.11.001>  
Reference: IJID 6484

To appear in: *International Journal of Infectious Diseases*

Received date: 14 October 2022  
Revised date: 31 October 2022  
Accepted date: 1 November 2022

Please cite this article as: Bryan Orons , Christopher Larson , Scott Caroen , Tony R. Reid , Could nucleocapsid be a next-generation COVID-19 vaccine candidate - author's reply, *International Journal of Infectious Diseases* (2022), doi: <https://doi.org/10.1016/j.ijid.2022.11.001>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.  
This is an open access article under the CC BY-NC-ND license  
(<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

**Title Page**

Title: Could nucleocapsid be a next-generation COVID-19 vaccine candidate - author's reply

Authors: Bryan Oronsky<sup>1\*</sup>, Christopher Larson<sup>1</sup>, Scott Caroen<sup>1</sup>, Tony R. Reid<sup>1</sup>

1. EpicentRx Inc., Torrey Pines, California, USA

\*Corresponding author: [boronsky@epicentrx.com](mailto:boronsky@epicentrx.com); 11099 North Torrey Pines Road, Torrey Pines California 92037, USA

This is in response to a letter to the editor by Saldivar-Espinoza *et al.*, commenting on a short perspective that we wrote in the September 2022 issue of the International Journal of Infectious Disease (IJID) entitled, “Nucleocapsid as a next-generation COVID-19 vaccine candidate” (Oronsky *et al.*, 2022). The main point of this perspective was that nucleocapsid, being highly conserved among coronaviruses, less mutable than spike, and strongly immunogenic especially for T cells (Lineburg *et al.*, 2021), which persist for much longer than waning antibodies, is a primary target for a broader and more cross-protective vaccine.

Based on an analysis of the GISAID (Global Initiative to Share All Influenza Data) repository Salvidar-Espinoza *et al.* responded with thought-provoking evidence that nucleocapsid (N) is, in fact, highly mutation prone in certain regions, second only to spike (S), which, in theory, may jeopardize the efficacy, and universality, of coronavirus (CoV) vaccines that incorporate N as an antigen. However, we are skeptical about the clinical relevance of this analysis for the following reasons.

Mutations are common in RNA viruses like SARS-CoV-2 (Duffy, 2018). Their rapid evolution is responsible for the accumulation of genetic changes, particularly when the host is immunodeficient. However, most mutations impact viral fitness deleteriously, especially those involving indispensable proteins like N, which not only binds to and protects the RNA genome from degradation but also functions as an antagonist of interferon (IFN), one of the main mechanisms of the host innate immune defense (Wu et al., 2021).

That this protein shares 90% homology with the severe acute respiratory syndrome coronavirus (SARS-CoV-1) N protein implies a conserved mechanism of nucleocapsid formation for CoVs (Bai et al., 2021). It also suggests that any nonsynonymous mutations in N, which change the amino acid sequence, and decrease the interaction between nucleocapsid, and RNA or that interfere with nucleocapsid formation as a result will negatively impact the fitness of the virus and *vice versa*. That said, genes do not operate in isolation but in concert with an array of other genes, and the synergic and antagonistic effects of epistatic interactions may profoundly impact whether these N mutations evolve under positive or negative selection, due to their impact on basic reproduction number ( $R_0$ ), immune evasion, generation time etc.

Accordingly, it is difficult, if not impossible, to attempt to predict the fate of individual mutations, and their relationship to a fitness phenotype, the better to determine which specific epitopes to include in a CoV vaccine given the myriad variables that are involved including population size, disease prevalence, within-host factors, and epistatic gene-gene interactions. For this reason, we are in favor of a self-replicating adenoviral-based vaccine that encodes the whole

nucleocapsid gene, including the regions “in the central disordered linker proximal to the N-G215C 28 mutation” identified by Saldivar-Espinoza *et al.* as the most conserved and stable.

#### **Conflict of Interest**

None

#### **Funding Source**

None

#### **Ethical Approval statement**

Not applicable

#### **References:**

1. Bai Z •Cao Y • Liu W• Li J. **The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation.** *Viruses*, 2021;**13**(6):1115. <https://doi.org/10.3390/v13061115>
2. Duffy S. **Why are RNA virus mutation rates so damn high?** *PLoS Biol.* 2018;**16**(8):e3000003. <https://doi.org/10.1371/journal.pbio.3000003>
3. Lineburg KE •Grant EJ •Swaminathan S et al. **CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses.** *Immunity.* 2021;**54**(5):1055-1065.e5. <https://doi.org/10.1016/j.immuni.2021.04.006>
4. Oronsky B •Larson C •Caroen S •Hedjran F •Sanchez A •Prokopenko E •Reid T. **Nucleocapsid as a next-generation COVID-19 vaccine candidate.** *Int J Infect Dis.* 2022 Sep;**122**:529-530. <https://doi.org/10.1016/j.ijid.2022.06.046>
5. Wu C •Qavi AJ •Hachim A et al. **Characterization of SARS-CoV-2 nucleocapsid protein reveals multiple functional consequences of the C-terminal domain.** *iScience.* 2021;**24**(6):102681. <https://doi.org/10.1016/j.isci.2021.102681>